Arterial stiffness determined from ambulatory blood pressure monitoring

controls (Mean SEM of cilnidipine 28.2 9.5, Mean SEM of active comparators 32 11.2; p1⁄40.8) Study designs include randomised, cross over design across the cardiovascular continuum including chronic kidney disease with cardiac hypertrophy, cerebrovascular disease. Conclusions: The equal distribution of patients across cilnidipine and amlodipine controlled arms reflects the strength of the study designs. These findings from our post hoc pooled analysis suggest that cilnidipine might be more effective than amlodipine; however this needs further confirmation by appropriately conducted larger RCCTs